Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific and Middle East: 1,908 cases from 40 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by topicWho?
by company- Teva Pharmaceutical Industries (Teva-Gruppe) €462.6m 81 % · 1 case
- Novamont S.p.A., Eni S.p.A. €32.1m 6 % · 1 case
- Anonymised companies €30.3m 5 % · 3 cases
- Vifor Pharma UK Limited u. a. (CSL-Konzern) €27.4m 5 % · 1 case
- Johnson & Johnson Consumer NV; Boehringer Ingelheim SComm; Haleon Belgium NV €11.2m 2 % · 1 case
- Hipolabor Farmacêutica Ltda., Sanval Comércio e Indústria Ltda., Comercial Cirúrgica Rioclarense Ltda. u. a. (5 Unternehmen) €7.15m 1 % · 1 case
- Viatris Inc. €1.8m 0 % · 1 case
- Bayer S.A. €773,398 0 % · 1 case
- Boehringer Ingelheim, Alkaloids of Australia, C2 PHARMA u. a. (7 Unternehmen) €645,231 0 % · 1 case
- Alchem International Pvt. Ltd. und Alchem International (H.K.) Limited €489,000 0 % · 1 case
- 2 more€0
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q4 2023 | 0 | – |
| Q1 2024 | 0 | – |
| Q2 2024 | 0 | – |
| Q3 2024 | 0 | – |
| Q4 2024 | 0 | – |
| Q1 2025 | 0 | – |
| Q2 2025 | 1 | €645,231 |
| Q3 2025 | 0 | – |
| Q4 2025 | 0 | – |
| Q1 2026 | 0 | – |
| Q2 2026 | 0 | – |
| Q3 2026 | 0 | – |
| Q4 2026 | 0 | – |
1 case
10 Apr 2025 Boehringer Ingelheim, Alkaloids of Australia, C2 PHARMA u. a. (7 Unternehmen)WEKO sanctions active-ingredient cartel over butylscopolamine bromide at around CHF 600,000 €645,231
Between 2005 and 2019 Boehringer Ingelheim, Alkaloids of Australia, Alkaloids Corporation, Alchem, C2 PHARMA, Linnea and Transo-Pharm set minimum selling prices for the active ingredient butylscopolamine bromide (SNBB), allocated quotas and exchanged sensitive business information. The Wettbewerbskommission (WEKO, Swiss Competition Commission) closed the case with amicable settlements; sanctions total around CHF 600,000, with C2 PHARMA as the self-reporting party exempted in full and Transo-Pharm and Linnea in part. It is the first cartel concerning a pharmaceutical active ingredient that WEKO has sanctioned.
Even small niche markets for intermediate products are watched by competition authorities, and the first to report can escape the sanction entirely.
Cartel risks for intermediate products and active ingredients; leniency programme
- Authority / court
- Wettbewerbskommission (WEKO)
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- Kartellgesetz (KG): Preis- und Mengenabrede, einvernehmliche Regelungen, Bonusregelung
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- Amicable settlements; full immunity for C2 PHARMA (leniency programme), partial reduction for Transo-Pharm and Linnea.
- Published
- 10 Apr 2025
Original amount 600,000 CHF, converted at the ECB reference rate of 10 Apr 2025.
- WEKO-Medienmitteilung vom 10.04.2025: WEKO sanktioniert Abrede über pharmazeutischen Wirkstoff Press release of an authority
- Newsroom-Schnittstelle der Bundesverwaltung: Volltext der WEKO-Medienmitteilung vom 10.04.2025 (onsb_de_105610) Press release of an authority
Checked against the official source on 2 Oct 2026 · Direct link